Aerie Pharmaceuticals Inc. intends to commercialize its glaucoma drug candidates itself, but positive Phase III results for both topical therapies, including new data for Roclatan, may make the company an acquisition target for biopharmaceutical firms that are looking to buy late-stage assets.
Irvine, Calif
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?